Advertisement

Protocol RACOP in the Treatment of Resistant and Relapsed ALL

  • R. A. Kutcher
  • V. G. Isaev
  • V. G. Savchenko
  • E. N. Parovitchnikova
  • L. S. Lubimova
  • L. P. Mendeleeva
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 37)

Abstract

A considerable success was achieved in adult ALL treatment, as the long-term disease-free survival for CR patients is reported to be 19–72% according to the risk factors [1,2,3]. But still relapses occur in many patients and account for most treatment failures. Another category of poor prognosis patients are those withrefractory disease (10–15%). The majority of treatment schedules for relapsed and resistant ALL now include high dose ARA-C (HD ARA-C) in combination with different cytostatic drugs and provide 38–64% of second CR [4,5,6,7] Taking in consideration the sufficient toxic (especially non-hematologic) effects of HD ARA-C regimens we introduced a new protocol RACOP and evaluated its efficacy in the high risk groups of patients.

Keywords

Acute Lymphoblastic Leukemia Cytosine Arabinoside Cytostatic Drug Poor Prognosis Patient Adult Acute Lymphoblastic Leukemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hoelzer D., Thiel E., Ludwig W.D., Loffler H., Buchner T., Freud M., Heil G., Hiddemann W., Maschmeyer G., Volkers B. Results of the German Multicenter Trials for Adult ALL. Haematological 1991; 76 (suppl 4): 106Google Scholar
  2. 2.
    Larson R.A., Burns C.P., Dodge R.K., George S.L., Bloomfield C.D., Davey F.R., Hooberman A.L.; Sobol R.E., Schiffer C.A. A 5-Drug Induction Regimen with Intensive Consolidation for Adult Acute Lymphoblastic Leukemia (ALL): Cancer and Leukemia Group B. Proc. Am. Soc. Clin. Oncol. 1992; 11: A864Google Scholar
  3. 3.
    Hoelzer D., Arnold R., Aydemir U., Buchner T., Freud M., W. Glassmann, N. Gokbuget, Hiddemann W., Koch P., Loffler H., Ludwig W.D., Maschmeyer G., Thiel E., Volkers B. Results of Intensified Consolidation Therapy in Four Consecutive German Multicenter Studies for Adult ALL. Blood 1993; 82(suppl 1): 193a (N 758)Google Scholar
  4. 4.
    Arlin Z.A., Feldman E., Kempin S., Ahmed T., Mittelman A., Savona S., Ascensao J., Baskind P., Sullivan Ph., Fuhr H.G., Mertelsmann R. Amsacrine with High-dose Cytarabine is Highly Effective Therapy for Refractory and Relapsed Acute Lymphoblastic Leukemia in Adults. Blood 1988; 72 (2) pp 433–435PubMedGoogle Scholar
  5. 5.
    Kantarjian H.M., Estey E.H., O’Brien S., Anaissie E., Beran M., Rios M.B., Keating M.J., Gutterman J. Intensive Chemotherapy with Mitoxantrone and High-dose Cytosine Arabinoside Followed by Granulocyte-Macrophage Colony-Stimulating Factor in the Treatment of Patients with Acute Lymphocytic Leukemia. Blood 1992; 79(4) pp 876–881PubMedGoogle Scholar
  6. 6.
    Freund M., Diedrich H., Ganser A., Gramatzky M., Heil G., Heyll A., Henke M., Hiddemann W., Haas R., Kuse R. et al Treatment of Relapsed or Refractory Adult Acute Lymphocytic Leukemia. Cancer 1992; 69 (3) pp 709–716PubMedCrossRefGoogle Scholar
  7. 7.
    Giona F., Annino L., Ferrari A., Crescenzi S., Aloe Spiriti M.A., Arcese W., Meloni G., Pigna M., Testi A.M., Mandelli F. Adult Acute Lymphoblastic Leukemia (ALL) Refractory or in Relapse: Results of Treatment over 17-yr Period. Haematological 1992; 76 (suppl 4): 67Google Scholar
  8. 8.
    Elias L., Shaw M.T., Raab S.O. Reinduction Therapy for Adult Acute Leukemia with Adriamycin, Vincristine, an Prednisone: a Southwest Oncology Group Study. Cancer Treat. Rep. 1979; 63 pp 1413–1415PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1996

Authors and Affiliations

  • R. A. Kutcher
    • 1
  • V. G. Isaev
    • 1
  • V. G. Savchenko
    • 1
  • E. N. Parovitchnikova
    • 1
  • L. S. Lubimova
    • 1
  • L. P. Mendeleeva
    • 1
  1. 1.National Research Center for HematologyMoscowRussia

Personalised recommendations